BM
Biomea Fusion, Inc.
BMEA · NASDAQ
$1.30 +2.36% (+$0.03)
1M -32.64%
Market Cap $94.0M
P/E Ratio -
Div. Yield -
ROE 171.19%
Bulios Fair Price
$1.06
18.5% downside
Current Price
$1.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMEA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
0/9Valuation
3 /100
Expensive P/B 7.74x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 35.19%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 212.95%
ROE 171.19%
ROA 88.24%
Debt
100 /100
Low Debt/Equity 0.07x
Current ratio 3.47x
Int. coverage N/A
Stability
35 /100
Moderate Beta -0.30x
EPS volatility 50.15%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMEA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael J. Hitchcock
Employees
37
Headquarters
San Carlos
Upcoming events
03 NOV
Earnings
Upcoming earnings report